More than 1,000 eye care professionals worldwide have been using the AdaptDx® and AdaptDx Pro™ to test for impaired dark adaptation, the earliest biomarker of age-related macular degeneration. Our customers tell the story of how they’re fighting against preventable blindness by identifying AMD at its earliest stages and closely monitoring its progression.
We are the first eye care provider to offer the AdaptDx test in Canada! I realized I owed it to my patients to offer this innovative test to help with the early detection and management of AMD. Now, my practice gets to be the one that inspires others here in Canada to begin managing AMD earlier than ever before!
Having been a Vision Source Administrator for nearly 15 years, I know the mindset of the prototypical Vision Source doctor, and it is this: Seek out and deliver optimal patient care using the most up-to-date technology that is based on the latest peer-reviewed research. While accomplishing this worthy goal, the Vision Source doctor also watches to be certain that this increased level of care will simultaneously enhance the practice’s business well-being and also save money for the overall health care system with early diagnosis and treatment. Having also been trained extensively on dark adaptometry technology, I can wholeheartedly say that the AdaptDx instrument checks every single box for the Vision Source practitioner to accomplish all of these patient goals in the early detection and treatment of subclinical AMD.
I have made performing an AdaptDx test on all my patients that are over the age of 60 years old my standard of care. I have found that about 40% fail the rapid test, even when the macula looks perfect clinically. This has helped me to be able to begin proactive measures with patients that previously would have been overlooked until there was more advanced disease.
I feel that the AdaptDx instrument from MacuLogix is the most significant medical device breakthrough in my career! We finally have an instrument that measures the earliest detectable signs of AMD. We can now diagnose AMD before vision loss occurs!
The AdaptDx is the kind of optometric instrument that once implemented in your practice makes you think how you did so without it all this time. The ability to find AMD years before seeing changes in the retina by photography or OCT makes it a medical necessity for my practice and patients. Once I learned about it, I could no longer neglect that segment of my practice and had to have it! It is easy to use, can be profitable, and is the right thing to do for my patients. And our patients deserve the best!
One of the great things about the AdaptDx is that it’s a very straightforward test to understand as a practitioner. It’s basically a yes-or-no test. If somebody has impaired dark adaptation, which means their ability to recover from a bright light takes longer than 6.5 minutes, we know with 90% sensitivity and specificity that the patient may have macular degeneration.
Having had the AdaptDx in my practice for almost 5 years has reinforced my confidence level in diagnosing AMD early with 90% sensitivity and specificity. My patients appreciate this technology and early diagnosis so that we can better monitor their progress and guide them with preventive measures. My patients recognize our practice as an AMD Center of Excellence with a commitment to preventing blindness through early diagnosis and management. MacuLogix has given our doctors the tool to be leaders in early AMD diagnosis.
Practices that have diversified into managing AMD are some of the most successful in the country and are well-positioned for the future.
The AdaptDx gives us the best gift of all: time to take appropriate action to slow the progression of the disease. All in all, this instrument is crucial in the early detection & disease management of AMD.
The MacuLogix AdaptDx performs a robust and reliable test of central retinal function and helps identify an early biomarker for age-related macular degeneration. The elegance of the instrument lies in its simplicity: an easy procedure for the patient, a short test duration, and an unambiguous data output for the clinician.